Contact
searchSearch
HMP Global

Multiple Myeloma Topic Center

Featured Article

News
Peripheral Residual Disease Monitoring Signals Progression Risk in Multiple Myeloma
10/18/2024
Peripheral residual disease identified using next-generation flow in patients with transplant-eligible multiple myeloma was associated with a 13-fold increased risk of progression or death, according to a clinical trial update published...
Peripheral residual disease identified using next-generation flow in patients with transplant-eligible multiple myeloma was associated with a 13-fold increased risk of progression or death, according to a clinical trial update published...
Peripheral residual disease...
10/18/2024
First Report Managed Care
Dimopoulos
Conference Coverage
Advancing Treatment Options for High-Risk Multiple Myeloma
10/02/2024
Discover how the addition of daratumumab to standard treatment improves outcomes for patients with high-risk cytogenetic abnormalities in multiple myeloma according to a SOHO 2024 presenter.
Discover how the addition of daratumumab to standard treatment improves outcomes for patients with high-risk cytogenetic abnormalities in multiple myeloma according to a SOHO 2024 presenter.
Discover how the addition of...
10/02/2024
First Report Managed Care
Conference Insider
Early Data Show Fast, Deep Responses With Teclistamab-Based Regimen for Multiple Myeloma
04/13/2023
Emma Searle, MD, PhD, reviews early data from MajesTEC-2, a trial designed to evaluate the recently approved monoclonal antibody teclistamab in combination with daratumumab and lenalidomide in patients with relapsed/refractory multiple...
Emma Searle, MD, PhD, reviews early data from MajesTEC-2, a trial designed to evaluate the recently approved monoclonal antibody teclistamab in combination with daratumumab and lenalidomide in patients with relapsed/refractory multiple...
Emma Searle, MD, PhD, reviews...
04/13/2023
First Report Managed Care
Conference Coverage
Oral, IV Multiple Myeloma Therapy Start Rates Significantly Increased During Pandemic
03/28/2023
Researchers speculated the increased therapy initiation rates may be explained by a significant decrease in the number of newly diagnosed patients.
Researchers speculated the increased therapy initiation rates may be explained by a significant decrease in the number of newly diagnosed patients.
Researchers speculated the...
03/28/2023
First Report Managed Care
Headshot of Dr Hira Shaikh, University of Iowa
Interview
Hispanic Ethnicity Associated With Worse Multiple Myeloma Outcomes, Study Shows
01/19/2023
Hira Shaikh, MD, assistant professor of hematology, oncology, and bone marrow transplant, University of Iowa Hospitals and Clinics, walks through the details of her study which compared multiple myeloma survival outcomes among Hispanic vs...
Hira Shaikh, MD, assistant professor of hematology, oncology, and bone marrow transplant, University of Iowa Hospitals and Clinics, walks through the details of her study which compared multiple myeloma survival outcomes among Hispanic vs...
Hira Shaikh, MD, assistant...
01/19/2023
First Report Managed Care
News
Combination Therapy for Multiple Myeloma Emerging as Standard of Care
12/22/2022
Authors shared updated efficacy and safety data from the phase 3 CANDOR study in which patients with relapsed or refractory multiple myeloma were treated with two combination therapy options.
Authors shared updated efficacy and safety data from the phase 3 CANDOR study in which patients with relapsed or refractory multiple myeloma were treated with two combination therapy options.
Authors shared updated efficacy...
12/22/2022
First Report Managed Care
News
Stem Cell Yield Adequate for Transplant After 4 Cycles of Daratumumab, Lenalidomide Quadruplet Induction for MM
12/21/2022
Researchers reviewed data from the MASTER and GRIFFIN trials to determine whether patients could undergo stem cell transplants after receiving induction therapy that included daratumumab and lenolidamide. 
Researchers reviewed data from the MASTER and GRIFFIN trials to determine whether patients could undergo stem cell transplants after receiving induction therapy that included daratumumab and lenolidamide. 
Researchers reviewed data from...
12/21/2022
First Report Managed Care
News
Real-World Treatment Patterns, Outcomes in Patients With Double- and Triple-Class R/R Multiple Myeloma
12/15/2022
Researchers studied a heavily pretreated patient population to determine which drugs were being administered, as well as their impact on overall survival.
Researchers studied a heavily pretreated patient population to determine which drugs were being administered, as well as their impact on overall survival.
Researchers studied a heavily...
12/15/2022
First Report Managed Care
News
Combination Regimen Prolongs Overall Survival in Relapsed/Refractory Multiple Myeloma
12/08/2022
The study participants received up to 8 cycles of bortezomib and dexamethasone, with or without daratumumab, until disease progression.
The study participants received up to 8 cycles of bortezomib and dexamethasone, with or without daratumumab, until disease progression.
The study participants received...
12/08/2022
First Report Managed Care
Literature Review
Anti-CD38 Monoclonal Antibody for Multiple Myeloma: A Review of Clinical Trials
11/29/2022
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming...
11/29/2022
First Report Managed Care
Headshot of Joshua Richter, MD, Mount Sinai
Interview
Analyzing First-line Therapy for Multiple Myeloma: Real-World Data Differs From Trials
10/18/2022
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual Meeting in which combination bortezomib,...
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual Meeting in which combination bortezomib,...
Joshua Richter, MD, associate...
10/18/2022
First Report Managed Care

Newsfeed

News
Peripheral Residual Disease Monitoring Signals Progression Risk in Multiple Myeloma
10/18/2024
Peripheral residual disease identified using next-generation flow in patients with transplant-eligible multiple myeloma was associated with a 13-fold increased risk of progression or death, according to a clinical trial update published...
Peripheral residual disease identified using next-generation flow in patients with transplant-eligible multiple myeloma was associated with a 13-fold increased risk of progression or death, according to a clinical trial update published...
Peripheral residual disease...
10/18/2024
First Report Managed Care
News
Combination Therapy for Multiple Myeloma Emerging as Standard of Care
12/22/2022
Authors shared updated efficacy and safety data from the phase 3 CANDOR study in which patients with relapsed or refractory multiple myeloma were treated with two combination therapy options.
Authors shared updated efficacy and safety data from the phase 3 CANDOR study in which patients with relapsed or refractory multiple myeloma were treated with two combination therapy options.
Authors shared updated efficacy...
12/22/2022
First Report Managed Care
News
Stem Cell Yield Adequate for Transplant After 4 Cycles of Daratumumab, Lenalidomide Quadruplet Induction for MM
12/21/2022
Researchers reviewed data from the MASTER and GRIFFIN trials to determine whether patients could undergo stem cell transplants after receiving induction therapy that included daratumumab and lenolidamide. 
Researchers reviewed data from the MASTER and GRIFFIN trials to determine whether patients could undergo stem cell transplants after receiving induction therapy that included daratumumab and lenolidamide. 
Researchers reviewed data from...
12/21/2022
First Report Managed Care
News
Real-World Treatment Patterns, Outcomes in Patients With Double- and Triple-Class R/R Multiple Myeloma
12/15/2022
Researchers studied a heavily pretreated patient population to determine which drugs were being administered, as well as their impact on overall survival.
Researchers studied a heavily pretreated patient population to determine which drugs were being administered, as well as their impact on overall survival.
Researchers studied a heavily...
12/15/2022
First Report Managed Care
News
Combination Regimen Prolongs Overall Survival in Relapsed/Refractory Multiple Myeloma
12/08/2022
The study participants received up to 8 cycles of bortezomib and dexamethasone, with or without daratumumab, until disease progression.
The study participants received up to 8 cycles of bortezomib and dexamethasone, with or without daratumumab, until disease progression.
The study participants received...
12/08/2022
First Report Managed Care
News
Comparing Cost-Effectiveness of 3 Treatment Regimens for Multiple Myeloma
12/29/2021
Combination lenalidomide plus dexamethasone was more cost-effective than 2 other treatment regimens in patients with multiple myeloma, though authors encouraged further analyses that include overall survival data.
Combination lenalidomide plus dexamethasone was more cost-effective than 2 other treatment regimens in patients with multiple myeloma, though authors encouraged further analyses that include overall survival data.
Combination lenalidomide plus...
12/29/2021
First Report Managed Care
News
Novel Multiple Myeloma Agents Can Add Years, but at High Costs
12/22/2021
Researchers conducted a systematic review of multiple myeloma treatment options to "provide physicians, payers, and policy makers with the necessary information for evidence-based decision making to ensure accessibility to promising novel...
Researchers conducted a systematic review of multiple myeloma treatment options to "provide physicians, payers, and policy makers with the necessary information for evidence-based decision making to ensure accessibility to promising novel...
Researchers conducted a...
12/22/2021
First Report Managed Care
News
Triple Regimen for Relapsed/Refractory Multiple Myeloma Feasible in Frail Patients
12/15/2021
A combination therapy demonstrated efficacy in frail older adults with relapsed/refractory multiple myeloma who had already received two or more therapies.
A combination therapy demonstrated efficacy in frail older adults with relapsed/refractory multiple myeloma who had already received two or more therapies.
A combination therapy...
12/15/2021
First Report Managed Care
News
Risk Factors Associated With Secondary Extramedullary Multiple Myeloma Development
12/08/2021
Younger age, extensive bone disease, and other factors were linked to an increased risk of developing secondary extramedullary multiple myeloma, according to findings published online ahead of print.
Younger age, extensive bone disease, and other factors were linked to an increased risk of developing secondary extramedullary multiple myeloma, according to findings published online ahead of print.
Younger age, extensive bone...
12/08/2021
First Report Managed Care
News
Costs Higher for Loss-of-Productivity With Injectable Chemotherapy for Multiple Myeloma
11/14/2018
According to study authors, “Our findings highlight the importance of considering indirect costs alongside efficacy, safety, and direct costs during the treatment decision-making process.”
According to study authors, “Our findings highlight the importance of considering indirect costs alongside efficacy, safety, and direct costs during the treatment decision-making process.”
According to study authors, “Our...
11/14/2018
First Report Managed Care
News
Emerging Treatments Improve Outcomes for Patients With Relapsed/Refractory Follicular Lymphoma
03/21/2025
Recent advancements in bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cell therapies are revolutionizing the treatment landscape for patients with relapsed or refractory follicular lymphoma (RR-FL), offering new hope for...
Recent advancements in bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cell therapies are revolutionizing the treatment landscape for patients with relapsed or refractory follicular lymphoma (RR-FL), offering new hope for...
Recent advancements in...
03/21/2025
First Report Managed Care
News
Biosimilars Gain Market Traction but Adoption Varies by Demographics and Other Factors
03/18/2025
Biosimilars are gaining market share and reducing drug costs, but patient adoption varies based on demographics, care settings, and payer policies.
Biosimilars are gaining market share and reducing drug costs, but patient adoption varies based on demographics, care settings, and payer policies.
Biosimilars are gaining market...
03/18/2025
First Report Managed Care
News
Patients With Vitiligo Face Elevated Risk of Cardiovascular Disease, Study Finds
03/14/2025
Individuals with vitiligo have an increased risk of major cardiovascular events, including stroke and venous thromboembolism, according to researchers.
Individuals with vitiligo have an increased risk of major cardiovascular events, including stroke and venous thromboembolism, according to researchers.
Individuals with vitiligo have...
03/14/2025
First Report Managed Care
News
Unlocking Cost-Efficiency and Access With Biosimilar Bevacizumab in Medicare
03/13/2025
New research shows significant cost savings and potential for expanded access to biosimilar bevacizumab in Medicare for patients with metastatic colorectal and non-small cell lung cancer.
New research shows significant cost savings and potential for expanded access to biosimilar bevacizumab in Medicare for patients with metastatic colorectal and non-small cell lung cancer.
New research shows significant...
03/13/2025
First Report Managed Care
News
Study Finds Limited Benefit of Common MS Fatigue Medications
03/12/2025
Commonly used medications for multiple sclerosis-related fatigue offer minimal clinical benefit and are more likely to cause treatment discontinuation due to side effects, according to a systematic review and meta-analysis published in...
Commonly used medications for multiple sclerosis-related fatigue offer minimal clinical benefit and are more likely to cause treatment discontinuation due to side effects, according to a systematic review and meta-analysis published in...
Commonly used medications for...
03/12/2025
First Report Managed Care
News
Bridging the Gap: Mental Health Support for Individuals With Skin Conditions
03/07/2025
A recently published review explores the impact of skin diseases on mental health, emphasizing the need for culturally sensitive approaches and digital health technologies to support individuals with skin conditions.
A recently published review explores the impact of skin diseases on mental health, emphasizing the need for culturally sensitive approaches and digital health technologies to support individuals with skin conditions.
A recently published review...
03/07/2025
First Report Managed Care
News
Bispecific Antibody Therapy Achieves Sustained Remissions in Follicular Lymphoma
03/06/2025
A 3-year follow-up of a phase 1/2 study confirms that mosunetuzumab, a CD20×CD3 bispecific antibody, provides durable remissions, high response rates, and a favorable safety profile in relapsed or refractory follicular lymphoma, reinforcing...
A 3-year follow-up of a phase 1/2 study confirms that mosunetuzumab, a CD20×CD3 bispecific antibody, provides durable remissions, high response rates, and a favorable safety profile in relapsed or refractory follicular lymphoma, reinforcing...
A 3-year follow-up of a phase...
03/06/2025
First Report Managed Care
News
Shifting Trends in Trastuzumab Utilization As Biosimilar Adoption Increases
03/05/2025
The use of trastuzumab for treating breast and other cancers has declined as trastuzumab biosimilars gain widespread adoption in the US.
The use of trastuzumab for treating breast and other cancers has declined as trastuzumab biosimilars gain widespread adoption in the US.
The use of trastuzumab for...
03/05/2025
First Report Managed Care
News
Revolutionizing Rural Medicine With AI-Powered Mobile Clinics
02/21/2025
A new initiative led by the University of Michigan is using artificial intelligence (AI)-driven mobile clinics to bring expert healthcare to underserved rural populations.
A new initiative led by the University of Michigan is using artificial intelligence (AI)-driven mobile clinics to bring expert healthcare to underserved rural populations.
A new initiative led by the...
02/21/2025
First Report Managed Care
News
Biosimilar Adalimumab Adoption Could Yield Millions in Cost Savings, Study Finds
02/20/2025
A financial analysis reveals that adopting biosimilar adalimumab in commercial health plans could lead to substantial cost savings with minimal medical cost implications.
A financial analysis reveals that adopting biosimilar adalimumab in commercial health plans could lead to substantial cost savings with minimal medical cost implications.
A financial analysis reveals...
02/20/2025
First Report Managed Care

Insights

Headshot of Dr Hira Shaikh, University of Iowa
Interview
Hispanic Ethnicity Associated With Worse Multiple Myeloma Outcomes, Study Shows
01/19/2023
Hira Shaikh, MD, assistant professor of hematology, oncology, and bone marrow transplant, University of Iowa Hospitals and Clinics, walks through the details of her study which compared multiple myeloma survival outcomes among Hispanic vs...
Hira Shaikh, MD, assistant professor of hematology, oncology, and bone marrow transplant, University of Iowa Hospitals and Clinics, walks through the details of her study which compared multiple myeloma survival outcomes among Hispanic vs...
Hira Shaikh, MD, assistant...
01/19/2023
First Report Managed Care
Headshot of Joshua Richter, MD, Mount Sinai
Interview
Analyzing First-line Therapy for Multiple Myeloma: Real-World Data Differs From Trials
10/18/2022
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual Meeting in which combination bortezomib,...
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual Meeting in which combination bortezomib,...
Joshua Richter, MD, associate...
10/18/2022
First Report Managed Care
Preliminary Efficacy, Safety Identified for Treatment Option for Patients With Multiple Myeloma
Videos
Preliminary Efficacy, Safety Identified for Treatment Option for Patients With Multiple Myeloma
12/05/2020
Alfred L Garfall, MD, MS, assistant professor of Medicine, Perelman School of Medicine, University of Pennsylvania, discusses his recent study presented at ASH 2020, which examined the use of teclistamab for the treatment of multiple myeloma,...
Alfred L Garfall, MD, MS, assistant professor of Medicine, Perelman School of Medicine, University of Pennsylvania, discusses his recent study presented at ASH 2020, which examined the use of teclistamab for the treatment of multiple myeloma,...
Alfred L Garfall, MD, MS,...
12/05/2020
First Report Managed Care
Analyzing the Use of CAR-T Therapy for the Treatment of Multiple Myeloma
Videos
Analyzing the Use of CAR-T Therapy for the Treatment of Multiple Myeloma
12/05/2020
Deepu Madduri, MD, assistant professor, Hematology and Medical Oncology of the Mount Sinai Hospital, Mount Sinai Beth Israel, discusses the results of the CARTITUDE-1 study, which analyzed ciltacabtagene autoleucel, a CAR-T-cell therapy with...
Deepu Madduri, MD, assistant professor, Hematology and Medical Oncology of the Mount Sinai Hospital, Mount Sinai Beth Israel, discusses the results of the CARTITUDE-1 study, which analyzed ciltacabtagene autoleucel, a CAR-T-cell therapy with...
Deepu Madduri, MD, assistant...
12/05/2020
First Report Managed Care
Interview
Identifying Major Unmet Medical Needs in Current Population of Myeloma Patients
02/22/2019
Ravi Vij, MD, MBA, from Washington University School of Medicine in St Louis, discusses his recent study findings that evaluated treatment sequences among patients with relapsed or refractory multiple myeloma after failure of...
Ravi Vij, MD, MBA, from Washington University School of Medicine in St Louis, discusses his recent study findings that evaluated treatment sequences among patients with relapsed or refractory multiple myeloma after failure of...
Ravi Vij, MD, MBA, from...
02/22/2019
First Report Managed Care

Behind the Bill

Behind the Bill
The $880 Billion Question Continues: Dr Oz's Confirmation and the Future of Medicaid
03/19/2025
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880...
03/19/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question: Can Congress Cut Spending Without Touching Medicaid?
03/12/2025
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from...
03/12/2025
First Report Managed Care
Behind the Bill
RFK Jr’s Public Comment Ban: The Silent Shift in Health Care Rulemaking
03/05/2025
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative...
03/05/2025
First Report Managed Care
Behind the Bill
Prevention Over Pills? The First 2 Weeks of Health Care’s New Direction
02/26/2025
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from...
02/26/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 2)
02/19/2025
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the...
02/19/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 1)
02/12/2025
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust...
02/12/2025
First Report Managed Care
Behind the Bill
No, President Trump Did Not Actually Sign an Executive Order That Would Increase Drug Costs for Beneficiaries
02/05/2025
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President...
02/05/2025
First Report Managed Care
Behind the Bill
Robert F. Kennedy Jr’s Confirmation and the Unexpected Turn in the Drug Pricing Debate
01/29/2025
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug...
01/29/2025
First Report Managed Care
Behind the Bill
Medicare Drug Negotiations 2.0: New Administration, Same Mission?
01/22/2025
Last week brought 2 major developments in health care policy: President Trump's inauguration and the Centers for Medicare and Medicaid Services’ (CMS) announcement of 15 additional drugs selected for Medicare price negotiations. While these...
Last week brought 2 major developments in health care policy: President Trump's inauguration and the Centers for Medicare and Medicaid Services’ (CMS) announcement of 15 additional drugs selected for Medicare price negotiations. While these...
Last week brought 2 major...
01/22/2025
First Report Managed Care
Behind the Bill
The First 100 Days: Health Care's Critical Deadlines in 2025
01/15/2025
The 119th Congress faces immediate health care deadlines amid significant leadership transitions. While much attention focuses on high-profile nominations like Dr Oz for Centers for Medicare and Medicaid Services (CMS) Administrator and...
The 119th Congress faces immediate health care deadlines amid significant leadership transitions. While much attention focuses on high-profile nominations like Dr Oz for Centers for Medicare and Medicaid Services (CMS) Administrator and...
The 119th Congress faces...
01/15/2025
First Report Managed Care

Subscribe and Stay Ahead With Daily Industry Insights

First Report Managed Care Newsletter

Trending Articles

Conference Coverage
Real-World Strategies for Implementing Biosimilars
04/12/2023
Speakers at AMCP 2023 discussed the current landscape of biosimilars from a payer perspective as well as lessons learned from health system biosimilar adoption. 
Speakers at AMCP 2023 discussed the current landscape of biosimilars from a payer perspective as well as lessons learned from health system biosimilar adoption. 
Speakers at AMCP 2023 discussed...
04/12/2023
First Report Managed Care
Headshot of Lisa Palko, PharmD, Akili Therapeutics
Interview
Evaluating a Prescription Digital Therapeutic for Pediatric Patients With ADHD
04/26/2023
Lisa Palko, PharmD, vice president of medical affairs, Akili Therapeutics, discusses an exploratory analysis which tested a prescription digital therapeutic's efficacy in pediatric patients with attention-deficit/hyperactivity disorder.
Lisa Palko, PharmD, vice president of medical affairs, Akili Therapeutics, discusses an exploratory analysis which tested a prescription digital therapeutic's efficacy in pediatric patients with attention-deficit/hyperactivity disorder.
Lisa Palko, PharmD, vice...
04/26/2023
First Report Managed Care
News
Value Assessment Tools: What Is Valuable to Payers?
05/26/2023
“US health care payers perceive select value assessment tools to be useful for informing health care decisions,” explained the authors of a recent study.
“US health care payers perceive select value assessment tools to be useful for informing health care decisions,” explained the authors of a recent study.
“US health care payers perceive...
05/26/2023
First Report Managed Care
Quiz
Understanding the Arexvy RSV Vaccine
06/20/2023
In a preliminary clinical trial, did the effectiveness of the now FDA-approved Arexvy vaccine vary based on the subtype of RSV?
In a preliminary clinical trial, did the effectiveness of the now FDA-approved Arexvy vaccine vary based on the subtype of RSV?
In a preliminary clinical trial,...
06/20/2023
First Report Managed Care
News
Clinics Integrating Digital Therapeutics for Alcohol Use Should Expect High Demand
07/19/2023
“Participants were enthusiastic about digital therapeutics for alcohol use disorder, anticipated high patient demand for such a resource, and made suggestions for successful implementation," researchers said.
“Participants were enthusiastic about digital therapeutics for alcohol use disorder, anticipated high patient demand for such a resource, and made suggestions for successful implementation," researchers said.
“Participants were enthusiastic...
07/19/2023
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use